The table below shows NovoCure Ltd's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Operating cash flow
-$13.52M
$20.57M
-$15.94M
-$35.66M
$10.38M
-$1.72M
Capital expenditure
$5.15M
$5.66M
$5.49M
$10.61M
$10.68M
$11.45M
Investing cash flow
$7.75M
$71.44M
$35.99M
-$6.47M
$10.19M
-$374.44M
Dividends paid
-
-
-
-
-
NVCR operating cash flow (10-K history)
NovoCure Ltd reported operating cash flow of -$49.03M for fiscal year 2025. That is down 85.9% from -$26.37M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$107.59M (FY 2016) to -$49.03M. Figures come from the company's audited annual reports as filed with the SEC.
